New implications of the proteolytic balance between matrix metalloproteinases and their tissue inhibitors in migraine with and without aura

Clinica Chimica Acta

Volumn 409, Issue 1-2, 2009, Pages 1-3

  Mannello, Ferdinando ^a  

^a UNIVERSITY OF URBINO   (Italy)

Author keywords

Headache; Matrix metalloproteinase 2 and 9; Migraine mechanism; Migraine with and without aura; Therapeutic application; Tissue inhibitor of metalloproteinase 1 and 2

Indexed keywords

GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSFORMING GROWTH FACTOR;

BLOOD BRAIN BARRIER; EDITORIAL; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; EXTRACELLULAR MATRIX; HUMAN; INFLAMMATION; MIGRAINE WITH AURA; MIGRAINE WITHOUT AURA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RISK FACTOR; SIGNAL TRANSDUCTION; SPREADING CORTICAL DEPRESSION;

FEMALE; GENE EXPRESSION REGULATION; HUMANS; MATRIX METALLOPROTEINASES; MIGRAINE DISORDERS; MIGRAINE WITH AURA; PERIODICALS AS TOPIC; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 70349835418     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2009.07.009     Document Type: Editorial

References (33)

1. Gross J., and Lapiere C.M. Collagenolytic activity in amphibian tissues: a tissue culture assay. Proc Natl Acad Sci U S A 48 (1962) 1014-1022
2. Malemud C.J. Matrix metalloproteinases (MMPs) in health and disease: an overview. Front Biosci 11 (2006) 1696-1701
3. Mannello F., Luchetti F., Falcieri E., and Papa S. Multiple roles of matrix metalloproteinases during apoptosis. Apoptosis 10 (2005) 19-24
4. Mannello F., Tonti G., Bagnara G.P., and Papa S. Role and function of matrix metalloproteinases in the differentiation and biological characterization of mesenchymal stem cell. Stem Cells 24 (2006) 475-481
5. Egebland M., and Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2 (2002) 161-174
6. Mannello F., Tonti G., and Papa S. Matrix metalloproteinase inhibitors as anticancer therapeutics. Curr Cancer Drug Target 5 (2005) 285-298
7. Mannello F., and Tonti G.A. Statins and breast cancer: may matrix metalloproteinase be the missing link?. Cancer Invest 27 (2009) 466-470
8. Visse R., and Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 92 (2003) 827-839
9. Brinckerhoff C.E., and Matrisian L.M. Matrix metalloproteinases: a tail of a frog that became a prince. Nature 3 (2002) 207-214
10. Mannello F. Natural bio-drugs as matrix metalloproteinase inhibitors: new perspectives on the horizon?. Recent Patent Drug Discov 1 (2006) 91-103
11. Mannello F., and Gazzanelli G. Tissue inhibitors of metalloproteinases and programmed cell death: conundrums, controversies and potential implications. Apoptosis 6 (2001) 479-482
12. Tonti G.A., Mannello F., Cacci E., and Biagioni S. Neural stem cells at the crossroads: MMPs may tell the way. Int J Dev Biol 53 (2009) 1-17
13. Yong V.W., Power C., Forsyth P., and Edwards D.R. Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci 2 (2001) 502-511
14. Goadsby P.J. Recent advances in understanding migraine mechanisms, molecules and therapeutics. Trend Mol Med 13 (2006) 39-44
15. Pietrobon D., and Striessnig J. Neurobiology of migraine. Nat Rev Neurosci 4 (2003) 386-398
16. Wessman M., Terwindt G.M., Kaunisto M.A., Palotie A., and Ophoff R.A. Migraine: a complex genetic disorder. Lancet Neurol 6 (2007) 521-532
17. Silberstein S.D. Migraine. Lancet 363 (2004) 381-391
18. International Classification of Headache Disorders. 2nd ed. Cephalalgia vol. 24 suppl.1 (2004) 9-160
19. Jensen R., and Stovner L.J. Epidemiology and comorbidity of headache. Lancet Neurol 7 (2008) 354-361
20. Gurney K.J., Estrada E.Y., and Rosenberg G.A. Blood-brain barrier disruption by stromelysin-1 facilitates neutrophils infiltration in neuroinflammation. Neurobiol Dis 23 (2006) 87-96
21. Edvinsson L., and Tfelt-Hansen P. The blood-brain barrier in migraine treatment. Cephalalgia 28 (2008) 1245-1258
22. Gursoy-Ozdemir Y., Qiu J., Matsuoka N., et al. Cortical spreading depression activates and upregulates MMP-9. J Clin Invest 113 (2004) 1447-1455
23. Leira R., Sobrino T., Rodriguez-Yanez M., Blanco M., Arias S., and Castillo J. MMP-9 immunoreactivity in acute migraine. Headache 47 (2007) 698-702
24. Imamura K., Takeshima T., Fusayasu E., and Nakashima K. Increased plasma matrix metalloproteinase-9 levels in migraineurs. Headache 48 (2007) 135-139
25. Martins-Oliveira A, Speciali JG, Dach F, et al. Different circulating metalloproteinases profiles in women with migraine with and without aura. Clin Chim Acta in press, doi:10.1016/j.cca.2009.07.008.
26. Gardner J., and Ghorpade A. Tissue inhibitor of metalloproteinase (TIMP)-1: the TIMPed balance of matrix metalloproteinases in the central nervous system. J Neurosci Res 74 (2003) 801-806
27. Fujimoto M., Tagagi Y., Aoki T., et al. Tissue inhibitor of metalloproteinases protect blood-brain barrier disruption in focal cerebral ischemia. J Cereb Blood Flow Metab 28 (2008) 1674-1685
28. Gardner J., Borgmann K., Deshpande M.S., et al. Potential mechanisms for astrocyte-TIMP-1 down-regulation in chronic inflammatory diseases. J Neurosci Res 83 (2006) 1281-1292
29. Dahr A., Gardner J., Borgmann K., Wu L., and Ghorpade A. Novel role of TGF-beta in differential astrocyte-TIMP-1 regulation: implications for HIV-1-dementia and neuroinflammation. J Neurosci Res 83 (2006) 1271-1280
30. Fernandez-Patron C., Radomski M.W., and Davidge S.T. Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circ Res 85 (1999) 906-911
31. Fernandez-Patron C., Stewart K.G., Zhang Y., Koivunen E., Radomski M.W., and Davidge S.T. Vascular matrix metalloproteinase-2-dependent cleavage of calcitonin gene-related peptide promotes vasoconstriction. Circ Res 87 (2000) 670-676
32. Haorah J., Ramirez S.H., Schall K., Smith D., Pandya R., and Persidsky Y. Oxidative stress activates protein tyrosine kinase and matrix metalloproteinases leading to blood-brain barrier disfunction. J Neurochem 101 (2007) 566-576
33. Lipton R.B., and Sheftell F.D. Moving forward - essential questions for the next 10 years. Headache 49 (2009) S43-S46